C4 Therapeutics Q3 EPS $(0.16) Beats $(0.22) Estimate, Sales $8.468M Miss $8.514M Estimate
Benzinga Newsdesk 15 hours ago
NewsEarningsEarnings BeatsEarnings Misses
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 63.64 percent increase over losses of $(0.44) per share from
C4 Therapeutics (NASDAQ:CCCC) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 63.64 percent increase over losses of $(0.44) per share from the same period last year. The company reported quarterly sales of $8.468 million which missed the analyst consensus estimate of $8.514 million by 0.54 percent. This is a 24.59 percent decrease over sales of $11.230 million the same period last year.